On Apr 7, 2016, we issued an updated research report on New Jersey-based Phibro Animal Health Corporation PAHC – a leading global diversified animal health and mineral nutrition company. The company provides a broad range of products for animals consumed as food, such as poultry, swine, beef and dairy cattle, and aquaculture.In the last reported second quarter of fiscal 2016, the company’s bottom line lagged the Zacks Consensus Estimate by a formidable margin but witnessed growth on a year-over-year basis.On the revenue front, year-over-year growth was sluggish, particularly because of an unimpressive international performance. According to Phibro, in the second fiscal quarter, the company witnessed tough currency challenges in its Animal Health segment, particularly in the dairy market.Moreover, significant customer consolidations are expected to consequently ramp up the product pricing pressures that Phibro’s business faces. Phibro also faces competition from generic alternatives of some of its products that may weigh on its future financial health and operational performance.However, Phibro is advancing well with its Animal Health product portfolio. The company is a leading provider of Medicated Feed Additives (MFA) products, with potential to gain hold on the huge and growing animal health market worldwide. Currently, the company is focused on expanding its footprint in the poultry, swine and cattle industries in both the domestic and international markets. The complementary nature of its animal health and mineral nutrition portfolio provides Phibro with unique cross-selling opportunities that can help it reach out to new customers or strengthen relationships with existing ones.Moreover, Phibro has been expanding its share in several significant emerging markets in the recent past. Of late, the company has ramped up penetration of some of its specialties in the dairy industry in the markets of Latin and South America. Also, it is expanding its dairy business in the markets of Australia, Brazil and Mexico. Further, the company’s distribution rights deal with MJ Biologics is expected to expand Phibro’s business in and out of North America.Currently, Phibro retains a Zacks Rank #3 (Hold).Key Picks in the SectorSome of the top-ranked medical products stocks are Baxter International Inc. BAX, Capricor Therapeutics, Inc. CAPR and Cardiovascular Systems Inc. CSII. All the three stocks carry a Zacks Rank #2 (Buy).Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PHIBRO ANIMAL (PAHC): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report CAPRICOR THERAP (CAPR): Free Stock Analysis Report CARDIOVASCLR SY (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research